News & Events

Remembering Daniel Schwartz

Comments Off on Remembering Daniel Schwartz

If you are a patient or caregiver who was helped by the GDATF in the last decade, you probably never met Daniel Schwartz. But as you called our toll-free hotline, pulled up one of our patient bulletins, searched for contact info for a local support group, or joined an online support forum discussion thread, Dan…

2021 Annual Appeal Letter

Comments Off on 2021 Annual Appeal Letter

Dear Friends,Like you, we couldn’t wait to say a not-so-fond farewell to 2020! However, in a lot of ways, 2021 brought more of the same. With our in-person educational events and support group meetings…

Welcome to the new gdatf.org!

Comments Off on Welcome to the new gdatf.org!

Welcome to the new gdatf.org! This project has been a long time in the making, and whether you are starting your journey with a new diagnosis – or have already traveled many miles with us – we hope you’ll feel at home here. The new site features an improved mobile experience (no more pinching and…

COVID-19 Resources

Comments Off on COVID-19 Resources

Visit us on YouTube to view our new webinar: Graves’ Disease, Thyroid Eye Disease and COVID-19 featuring Dr. Terry Smith and Dr. Don Kikkawa. (Approx. running time is 60 minutes). Stuck at home? Connect with your fellow patients online! We have several formats available for online support, including oneGRAVESvoice (a collaboration between the GDATF, Horizon Therapeutics, and rareLife solutions), the…

Neuropsychiatric Symptoms and Graves’

Comments Off on Neuropsychiatric Symptoms and Graves’

(Originally posted on July 2, 2019 and February 24, 2021.) If you enjoyed the GDATF’s patient bulletin “What’s Wrong With Me? I’m Not Myself Anymore”, then you won’t want to miss the sequel! “A survey study of neuropsychiatric complaints in patients with Graves’ disease: A reassessment of self-reported symptoms and current practice 20 years later” is now…

Webinar on the Long-Term Use of Antithyroid Drugs

Comments Off on Webinar on the Long-Term Use of Antithyroid Drugs

Did you miss our webinar on long-term use of antithyroid medication featuring Dr. Eve Bloomgarden (Northwestern Medicine) and Dr. David Cooper (Johns Hopkins Medicine)? See below to view the program in its entirety on YouTube! Huge thanks to Dr. Bloomgarden and Dr. Cooper for taking time on a Saturday to share their expertise on one of our most requested topics!

GDATF 2020 Annual Appeal Letter

Comments Off on GDATF 2020 Annual Appeal Letter

(Originally posted on December 8, 2020) To our valued community members, Wow, what a decade the last year has been! As 2020 kicked off, the future was so bright, we had to wear shades. (Of course, we always sport protective eyewear when heading out into the elements – thanks to light sensitivity from thyroid eye…

Remembering Dr. Noel Rose

Comments Off on Remembering Dr. Noel Rose

(Originally Posted on August 6, 2020) We were saddened to learn that Dr. Noel R. Rose, a pioneer in the field of autoimmunity and a former GDATF Board member, recently passed away at his home in Brookline, MA. His research on Hashimoto’s disease dates back to the 1950s at the University of Buffalo School of…

Rules for Online Communities

Comments Off on Rules for Online Communities

Did you know that the GDATF hosts a moderated Facebook group for patients? The group is closed – which means that group posts and comments can only be viewed by members. In order to join the group, visit our Facebook Page. Select “Join Group” – which is typically in the top right-hand corner, but might be in a different spot depending on whether you are connecting via…

Tepezza (teprotumumab-trbw) Receives FDA Approval

Comments Off on Tepezza (teprotumumab-trbw) Receives FDA Approval

(Originally posted January 21, 2020 and March 1, 2019) BREAKING NEWS: The FDA has approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease. Wiley Chambers, M.D., deputy director of the Division of Transplant and Ophthalmology Products in the FDA’s Center for Drug Evaluation and Research noted, “Today’s approval marks an important milestone for…